Novo Nordisk’s gene silencing alliance with Dicerna bears first fruitTwo years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a Share XNovo Nordisk’s gene silencing alliance with Dicerna bears first fruithttps://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/
Lilly surges on positive phase 3 readout from diabetes contenderEli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be Share XLilly surges on positive phase 3 readout from diabetes contenderhttps://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/
First results of the DiabetRisk studyFirst results of the DiabetRisk study Share XFirst results of the DiabetRisk studyhttps://pharmaphorum.com/partner-content/first-results-of-the-diabetrisk-study/
Helixmith starts new trial of diabetic neuropathy gene therapyJust over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic Share XHelixmith starts new trial of diabetic neuropathy gene therapyhttps://pharmaphorum.com/r-d/helixmith-starts-new-trial-of-diabetic-neuropathy-gene-therapy/
Towards a new understanding of cardiovascular risk in diabetesA new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is Share XTowards a new understanding of cardiovascular risk in diabeteshttps://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/
Pharma’s response to COVID-19: Lilly and diabetes careAs part of our series looking at how pharma companies have adapted to the pandemic, Shannon Rush, leader Share XPharma’s response to COVID-19: Lilly and diabetes carehttps://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-response-to-covid-lilly-and-diabetes-care/
Novo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnNovo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion, as it continues its quest to develop Share XNovo Nordisk to buy Emisphere and diabetes pill tech for $1.8bnhttps://pharmaphorum.com/news/novo-nordisk-to-buy-emisphere-and-diabetes-pill-tech-for-1-8bn/
Sensyne Health launches diabetes app in the UKUK digital health company Sensyne Health has launched a new smartphone app to help people across the diabetes Share XSensyne Health launches diabetes app in the UKhttps://pharmaphorum.com/news/sensyne-health-launches-diabetes-app-in-the-uk/
Novo Nordisk beats Q2 profit forecasts by cutting costsDenmark’s Novo Nordisk has beaten profit forecasts in the second quarter after overcoming tough conditions in the diabetes Share XNovo Nordisk beats Q2 profit forecasts by cutting costshttps://pharmaphorum.com/news/novo-nordisk-beats-q2-profit-forecasts-by-cutting-costs/